Pathogenesis of aspirin-exacerbated respiratory disease

Clinical Reviews in Allergy and Immunology

Volumn 24, Issue 2, 2003, Pages 169-187

  Stevenson, Donald D ^a   Zuraw, Bruce L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Aspirin exacerbated respiratory disease (AERD); Cysteinyl leukotriene receptors (cysLTR); Leukotriene A4 (LTA4); Leukotriene E4 (LTE4); Leukotrienes (LTs); Prostaglandin E2 (PGE2)

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYTOKINE; DIPHENHYDRAMINE; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUKOTRIENE; LEUKOTRIENE A4; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; PROSTAGLANDIN G2; PROSTANOID; RANITIDINE;

ABDOMINAL PAIN; ARACHIDONIC ACID METABOLISM; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; DESENSITIZATION; DIARRHEA; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; EOSINOPHIL; EPITHELIUM CELL; FLUSHING; GASTROINTESTINAL SYMPTOM; GENETIC REGULATION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; MAST CELL; NOSE POLYP; PATHOGENESIS; RESPIRATORY TRACT DISEASE; REVIEW; RHINOSINUSITIS; SINUSITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG HYPERSENSITIVITY; HUMANS; ISOENZYMES; LEUKOTRIENES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RESPIRATORY HYPERSENSITIVITY;

EID: 0037389441     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:24:2:169     Document Type: Review

References (104)

1. Vane, J. R. (1971), Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232-235.
2. Zembowicz, A., Jones, S. L., and Wu, K. K. (1995), Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J. Clin. Investig. 96, 1688-1692.
3. Hawley, C. (1999), COX-2 inhibitors. Lancet 353, 307-314.
4. Samuelsson, B., Hammarstroem, S., Murphy, R. C., and Borgeat, P. (1980), Leukotrienes and slow reacting substance of anaphylaxis (SRS-A). Allergy 35, 375-381.
5. Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A., and Serhan, C. N. (1987), Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. [Review.] Science 237, 1171-1176.
6. Szczeklik, A. and Stevenson, D. D. (1999), Aspirin-induced asthma: advances in pathogenesis and management. J. Allergy Clin. Immunol. 104, 5-13.
7. Moneret-Vautrin, D. A., Hsieh, V., Wayoff, M., Guyot, J. L., Mouton, C., and Maria, Y. (1990), Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. Ann. Allergy 64, 513-518.
8. Yamashita, T., Tsuyi, H., Maeda, N., Tomoda, K., and Kumazawa, T. (1989), Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinology 8, 15-24.
9. Nasser S. M., Pfister, R., Christie, P. E., Sousa, A. R., Barker, J., Schmitz-Schumann, M., et al. (1996), Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am. J. Respir. Crit. Care Med. 153, 90-96.
10. Sousa, A., Pfister, R., Christie, P. E., Lane, S. J., Nasser, S. M., Schmitz-Schumann, M., et al. (1997), Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 52, 940-945.
11. Sousa, A. R., Lams, B. E., Pfister, R., Christie, P. E., Schmitz, M., and Lee, T. H. (1997), Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am. J. Respir. Crit. Care Med. 156, 1384-1389.
12. Sladek, K., Dworski, R., Soja, J., Sheller, J. R., Nizankowska, E., Oates, J. A., et al. (1994), Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am. J. Respir. Crit. Care Med. 149, 940-946.
13. Kowalski, M., Grzegorczy, J., Wojciechowska, B., and Sponiatowska, M. (1996), Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin. Exp. Allergy 26, 807-814.
14. Borish, L. (2002), Sinusitis and asthma: entering the realm of evidence-based medicine. J. Allergy Clin. Immunol. 109, 606-607.
15. Hamilos, D., Leung, D. Y. M., Wood, R., Cunningham, L., Bean, D. K., and Yasruel, Z. (1995), Evidence for distinct cytokine expression in allergic versus non-allergic chronic sinusitis. J. Allergy Clin. Immunol. 96, 537-544.
16. Bachert, C., Wagenmann, M., Hauser, U., and Rudack, C. (1997), IL-5 synthesis is upregulated in human nasal polyp tissue. J. Allergy Clin. Immunol. 99, 837-842.
17. Kowalski, M. L., Grzegorczyk, J., Pawliczak, R., Kornatowski, T., Wagrowska-Danilewicz, M., and Danilewicz, M. (2002), Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. Allergy 57, 493-500.
18. Bachert, C., Wagenmann, M., Rudack, C., Hopken, K., Hillebrandt, M., Wang, D., and Van Cauwenberge, P. (1998), The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 53, 2-13.
19. Settipane, G. A. (1987), Nasal polyps: pathology, immunology and treatment. Am. J. Rhinol. 1, 119-126.
20. Stevenson, D. and Simon, R. A. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs, in Allergy: Principles and Practice, Middleton, E., Jr., Ellis, E. F., Yunginger, J. W., Reed, C. E., Adkinson, N. F., Jr., and Busse, W. W., eds., vol 2, 5th ed., Mosby, St. Louis, 1998, pp. 1225-1234.
21. Stevenson, D. (2000), Approach to the patient with a history of adverse reactions to aspirin or NSAIDs: diagnosis and treatment. Allergy and Asthma Proceedings 21, 25-31.
22. Kakoi, H. and Hiraide, F. A. (1987), A histologic study of formation and growth of nasal polyps. Acta Otolaryngol. 103, 137-144.
23. Bachert, C., Gevaert, P., and Van Cauwengerge, P. (1999), Nasal polyposis - a new concept on the formation of polyps. ACI International 11, 130-135.
24. Elsner, J., Hochstetter, R., Kimming, D., and Kapp, A. (1996), Human eotaxin represents a potent activator of the respiratory burst in human eosinophils. Eur. J. Immunol. 26, 1919-1925.
25. Mullol, J., Ferandez-Morata, J. C., Roca-Ferrer, J., Pujols, L., Xaubet, A., Benitez, P., et al. (2002), Cyclooxygenase 1 and 2 expression is abnormally regulated in human nasal polyps. J. Allergy Clin. Immunol. 109, 824-830.
26. Christie, P. E., Tagari, P., Ford-Hutchinson, A. W., Charlesson, S., Chee, P., Arm, J. P., et al. (1991), Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143, 1025-1029.
27. Smith, C. M., Hawksworth, R. J., Thien, F. C., Christie, P. E., and Lee, T. H. (1992), Urinary leukotriene E4 in bronchial asthma. Eur. Respir. J. 5, 693-699.
28. Kumlin, M., Dahlen, B., Bjorck, T., Zetterstrom, O., Granstrom, E., and Dahlen, S. E. (1992), Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am. Rev. Respir. Dis. 146, 96-103.
29. Knapp, H. R., Sladek, K., and Fitzgerald, G. A. (1992), Increased excretion of leukotriene E4 during aspirin-induced asthma. J. Lab. Clin. Med. 119, 48-51.
30. Sladek, K. and Szczeklik, A. (1993), Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6, 391-399.
31. Daffern, P., Muilenburg, D., Hugli, T. E., and Stevenson, D. D. (1999), Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J. Allergy Clin. Immunol. 104, 559-564.
32. Kohno, S. (1998), Lipid mediators in bronchial asthma. Allergy Clin. Immunol. International 10, 181-186.
33. Schmid, M., Gode, U., Schafer, D., and Wigand, M. E. (1999), Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Acta Otolaryngol. 119, 277-280.
34. Cowburn, A. S., Sladek, K., Soja, J., Adamek, L., Nizankowska, E., Szczeklik, A., et al. (1998), Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Investig. 101, 834-846.
35. Takasaki, J. K. M. and Matsumoto, M. (2000), The molecular characterization and tissue distribution of the human cysteinyl leukotriene cys LT (2) receptor. Biochem. Biophys. Res. Commun. 274, 316-322.
36. Szczeklik, A., Sladek, K., Dworski, R., Nizankowska, E., Soja, J., and Oates, J. (1996), Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 154, 1608-1614.
37. Braccioni, F., Dorman, S. C., O'Byrne, P. M., Inman, M. D., Denburg, J. A., Parameswaran, K., et al. (2002), The effect of cysteinyl leukotrienes on the growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J. Allergy Clin. Immunol. 110, 96-101.
38. Spada, C., Nieves, A. L., Krauss, A. H., and Woodward, D. F. (1994), Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J. Leukoc. Biol. 55, 183-191.
39. Mita, H., Endoh, S., Kudoh, M., Kawagishi, Y., Kobayashi, M., Taniguchi, M., et al. (2001), Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 56, 1061-1067.
40. Ferreri, N. R., Howland, W. C., and Spiegelberg, H. L. (1986), Release of leukotrienes C4 and B4 and PGE2 from human monocytes stimulated with aggregated IgG, IgA and IgE. J. Immunol. 136, 4188-4193.
41. Ziroli, N. E., Na, H., Chow, J. M., Stankiewicz, J. A., Samter, M., and Young, M. R. (2002), Aspirin-sensitive versus non-aspirin-sensitive nasal polyp patients: analysis of leukotrienes/Fas and Fasligand expression. Otolaryngol. Head Neck Surg. 126, 141-146.
42. Holtzman, M. J., Turk, J., and Shornick, L. P. (1992), Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J. Biol. Chem. 267, 21,438-21,445.
43. Demoly, P., Jaffuel, D., Lequex, B., Cremion, C., Michel, F., Godard, P., et al. (1997), Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics. Am. J. Respir. Crit. Care Med. 155, 670-675.
44. Smith, W. L. and Dewitt, D. L. (1996), Cycloogygenase enzymes: a review. Adv. Immunol. 62, 167-215.
45. Picado, C., Fernandez-Morata, J. C., Juan, M., Roca-Ferrer, J., Fuentes, M., Xaubet, A., et al. (1999), Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 160, 291-296.
46. Lynch, K. R., O'Neill, G. P., Liu, Q., Im, D. S., Sawyer, N., Metters, K. M., et al. (1999), Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399, 789-793.
47. Saru, H., Ames, R. S., Chambers, J., Ellis, C., Elshourbagy, N., and Foley, J. J. (1999), Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol. Pharmacol. 56, 657-663.
48. Figueroa, D. J., Breyer R. M., Defoe, S. K., Kargman, S., Daugherty, B. L., Waldburger, K., Liu, Q., et al. (2001), Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral leukocytes. Am. J. Respir. Crit. Care Med. 163, 226-233.
49. Heise, C. E. O. D. B. and Figuero, D. J. (2000), Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275, 30,531-30,536.
50. James, A. and Sampson, A. P. (2001), A tale of Two CysLTs. Clin. Exp. Allergy 31, 1660-1664.
51. Mita, H., Hasegawa, M., Saito, H., and Akiyama, K. (2001), Levels of cysteinyl leukotiene receptor mRNA in human peripheral leukocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin. Exp. Allergy 31, 1716-1725.
52. Arm, J. P., O'Hickey, S. P., Spur, B. W., and Lee, T. H. (1989), Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am. Rev. Respir. Dis. 140, 148-153.
53. Christie, P. E., Smith, C. M., and Lee, T. H. (1991), The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am. Rev. Respir. Dis. 144, 957-958.
54. Stevenson, D., Simon, R. A., Mathison, D. A., and Christiansen, S. C. (2000), Montelukast is only partially effective in inhibiting aspirin responses in aspirin sensitive asthmatics. Ann. Allergy Asthma Immunol. 85, 477-482.
55. Dahlen, S., Malstrom, K., Nizankowska, E., Dahlen, B., Kuna, P., Kowalski, M., et al. (2002), Improvement of aspirin-intolerant asthma by montelukast, a leukotriene anatagonist. A randomised, double blind, placebo controlled trial. Am. J. Respir. Crit. Care Med. 165, 9-14.
56. Szczeklik, A., Nizankowska, E., Mastalerz, L., and Bochenek, G. (2002), Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J. Allergy Clin. Immunol. 109, 572-573.
57. Serhan, C. N. (2001), Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of anti-inflammation: emergence of the counterregulatory side. Arch. Immunol. Ther. Exp. 49, 177-188.
58. Sanak, M., Levy, B. D., Clish, C. B., Chiang, N., Gronert, K., Mastalerz, L., et al. (2000), Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16, 44-49.
59. Szczeklik, A., Nizankowska, E., and Duplaga, M. (2000), Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur. Respir. J. 16, 432-436.
60. Berges-Gimeno, M., Simon, R. A., and Stevenson, D. D. (2002), The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 89, 474-478
61. Szczeklik, A. (1990), The cyclooxygenase theory of aspirin-induced asthma. [Review.] Eur. Respir. J. 3, 588-593.
62. Nakagawa, H., Yoshida, S., Nakabayashi, M., Akahori, K., Shoji, T., Hasegawa, H., et al. (2001), Possible relevance of virus infection for development of analgesic idiosyncrasy. Respiration 68, 422-424.
63. Brookes, A. (1999), The essence of SNPs. Gene 234, 177-186.
64. Sanak, M., Simon, Hans-Uwe, and Szxzeklik, A. (1997), Leukotriene C4 synthase promotor polymorphism and risk of aspirin-induced asthma. Lancet 350, 1599-1600.
65. Penrose, J. F. and Baldasaro, M. H. (1999), Leukotriene C4 synthase: a candidate gene for the aspirin-intolerant asthmatic phenotype. Allergy Asthma Proc. 20, 353-360.
66. Szczeklik, A., Sanak, M., Nizankowska, E., Mastalerz, L., Bochenek, G., and Pulka, G. (1998), Leukotriene C4 synthase genetic polymorphism directs urinary cysteinyl-leukotiene response to aspirin challenge in asthma. Allergy 53, 61-67.
67. Sanak, M. and Szczeklik, A. (2000), Genetics of aspirin induced asthma. Thorax 55, S45-S47.
68. Van Sambeek, R. S. D., Baldasaro, M., Lam, B. K. Z. J., Yoshida, S., Yandora, C., and Drazen, J. M. P. J. (2000), 5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J. Allergy Clin. Immunol. 106, 72-76.
69. Kawagishi, K., M. H., Taniguchi, M., Maruyama, M., Oosaki, R., Higashi, N., Kashii, T., et al. (2002), Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J. Allergy Clin. Immunol. 109, 936-942.
70. Bigby, T. (2000), The leukotriene C4 synthase gene and asthma. Am. J. Respir. Cell Mol. Biol. 23, 273-276.
71. Pleskow, W. W., Stevenson, D. D., Mathison, D. A., Simon, R. A., Schatz, M., and Zieger, R. S. (1983), Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J. Allergy Clin. Immunol. 71, 574-579.
72. Lewis, R. A. and Austen, K. F. (1984), The biologically active leukotrienes: biosynthesis, metabolism, receptors, functions, and pharmacology. J. Clin. Investig. 73, 889-902.
73. Dahlen, B. J., Kumlin, M., Margolskee, D., Larsson, C., Blomqvist, H., Williams, V. C., et al. (1993), The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by bronchial provocation with lysine-aspirin in aspirin-sensitive asthmatics. Eur. Respir. J. 6, 1018-1026.
74. Israel, E., Fischer, A. R., Rosenberg, M. A., Lilly, C. M., Callery, J. C., Shapiro, J., et al. (1993), The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Resp. Dis. 148, 1447-1451.
75. Szczeklik, A. and Serwonska, M. (1979), Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clematine. Thorax 34, 654-658.
76. Ferreri, N. R., Howland, W. C., Stevenson, D. D., and Spiegelberg, H. L. (1988), Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am. Rev. Respir. Dis. 137, 847-854.
77. Fischer, A. R., Rosenberg, M. A., Lilly, C. M., Callery, J. C., Rubin, P., Cohn, J., et al. (1994), Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J. Allergy Clin. Immunol. 94, 1046-1056.
78. Kowalski, M. L., Sliwinska-Kowalska, M., Igarashi, Y., White, M. V., Wojciechowska, B., Brayton, P., et al. (1993), Nasal secretions in response to acetylsalicylic acid. J. Allergy Clin. Immunol. 91, 580-598.
79. Picado, C., Ramis, I., Rosello, J., Prat, J., Bulbena, O., Plaza, V., et al. (1992), Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am. Rev. Respir. Dis. 145, 65-69.
80. Berges-Gimeno, M., Simon, R. A., and Stevenson, D. D. (2002), The effect of leukotriene modifier drugs on asa-induced asthma and rhinitis reactions. Clin. Exp. Allergy.
81. Bianco, S. R. M. and Petrini, G. (1977), Aspirin induced tolerance in aspirin-asthma detected by a new challenge test. IRCS J. Med. Sci. 5, 129-136.
82. Schmitz-Schumann, V. M., Juhl, E., and Costabel, U. (1985), Analgesic asthma-provocation challenge with acetylsalicylic acid. Atemwegs-Lungenkrankh Jahrgang 10, 479-485.
83. Kuna, P., Zielinska, E., Bpchenska-Marciniak, M., and Rozniecki, J. (1997), Early and late asthmatic response after inhalation challenge with lysine-ASA in subjects with aspirin-induced asthma. J. Allergy Clin. Immunol. 99, S411 (Abstract #1669).
84. Dahlen, B. and Melillo, G. (1998), Inhalation challenge in ASA-induced asthma. Respir. Med. 92, 378-384.
85. Patriarca, G., Nucera, E., and Di Rienzo, V. (1991), Nasal provocation test with lysine acetylsalicylate (LAS) in aspirin-sensitive patients. Ann. Allergy 67, 60-62.
86. Bosso, J. V., Schwartz, L. B., and Stevenson, D. D. (1991), Tryptase and histamine release during aspirin-induced respiratory reactions. J. Allergy Clin. Immunol. 88, 830-837.
87. Stevenson, D. and Simon, R. A. (2001), Lack of cross-reactivity between rofecoxib and aspirin in aspirin sensitive asthmatic patients. J. Allergy Clin. Immunol. 108, 47-51.
88. Woessner, K., Simon, R. A., and Stevenson, D. D. (2002), The safety of celecoxib in aspirin exacerbated respiratory disease. Arthritis Rheum. 46, 2201-2206.
89. Juergens, U. R., Christiansen, S. C., Stevenson, D. D., and Zuraw, B. L. (1992), Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients before and after oral aspirin challenge. J. Allergy Clin. Immunol. 90, 636-645.
90. Stevenson, D. D., Arroyave, C. M., Bhat, K. N., and Tan, E. M. (1976), Oral aspirin challenges in asthmatic patients: a study of plasma histamine. Clin. Allergy 6, 493-505.
91. Dahlen, B., Boreus, L. O., Anderson, P., Andersson, R., and Zetterstrom, O. (1994), Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects. Allergy 49, 43-49.
92. Sestini, P., Armetti, L., Gambaro, G., Pieroni, M. G., Refini, R. M., Sala, A., et al. (1996), Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 153, 572-575.
93. Szczeklik, A., Mastalerz, L., Nizankowska, E., and Cmiel, A. (1996), Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 153, 567-571.
94. Szmidt, M. and Wasiak, W. (1996), The influence of misoprostol (synthetic analogue of prostaglandin E1) on aspirin-induced bronchoconstriction in aspirin-sensitive asthma. J. Investig. Allergol. Clin. Immunol. 6, 121-125.
95. Kowalski, M., Ptasinski, A., Bienkiewics, B., and DuBuske, L. M. (2002), Aspirin-induced 15-HETE generation is a specific aspirin-sensitive asthma/rhinosinusitis patient identification test. J. Allergy Clin. Immunol. 209, S30.
96. Antczak, A., Montuschi, P., Kharitonov, S., Gorski, P., and Barnes, P. J. (2002), Increased exhaled cystieinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 166, 301-306.
97. Nasser, S., Christie, P. E., Pfister, R., Sousa, A. R., Walls, A., Schmitz-Schumann, M., et al. (1996), Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 51, 64-70.
98. Christie, P. E., Tagari, P., Ford-Hutchinson, A. W., Black, C., Markendorf, A., Schmitz-Schumann, M., et al. (1992), Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am. Rev. Respir. Dis. 146, 1531-1534.
99. Kowalski, M. L., Pawliczak, R., Wozniak, J., Siuda, K., Poniatowska, M., Iwaszkiewicz, J., et al. (2000), Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am. J. Respir. Crit. Care Med. 161, 391-398.
100. Juergens, U. R., Christiansen, S. C., Stevenson, D. D., and Zuraw, B. L. (1995), Inhibition of monocyte leukotriene B4 production following aspirin desensitization. J. Allergy Clin. Immunol. 96, 148-156.
101. Berges-Gimeno, M., Simon, R. A., and Stevenson, D. D. (2003), Early effects of aspirin desensitization treatment in asthmatics with aspirin exacerbated respiratory disease. Ann. Allergy Clin. Immunol.
102. Nasser, S. M. S., Patel, M., Bell, G. S., Lee, T. H. (1995), The effect of aspirin desensitization on urinary leukotriene E4 concentration in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 151, 1326-1330.
103. Kopp, E. and Ghosh, S. (1994), Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265, 956-959.
104. Perez, G. M., Melo, M., Keegan, A. D., and Zamorano, J. (2002), Aspirin and salicylates inhibit the IL-4 and IL-13 induced activation of STAT6. J. Immunol. 168, 1428-1434.